5th Binaytara Precision Oncology Summit: Redefining Cancer Treatment with Molecular Targeted Strategies

Accreditation: 10.25 ABIM MOC II | 10.25 Nursing Contact Hours | 10.25 ACPE Pharmacy | 10.25 AMA PRA Category 1 Credit™

Venue: InterContinental San Francisco, 888 Howard Street, San Francisco, CA, United States

Start Date: October 24End Date: October 25, 2025

Faculty disclosures

Identification and mitigation of potential conflicts of interest

All conflict of interest has been identified and mitigated for individuals in control of contents.

Planning committee disclosure statement

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Conference Chair

No, I have not had a financial relationship with an ineligible company within the past 24 months.

Session Chairs

has a financial relationship (Consultant) with Bristol-Myers Squibb; financial relationship (Advisor) with Bristol-Myers Squibb; financial relationship (Consultant) with Gilead; financial relationship (Consultant) with Janssen; financial relationship (Advisor) with Janssen; financial relationship (Advisor) with Jazz Pharamceuticals; financial relationship (Advisor) with Regeneron; financial relationship (Advisor) with Genentech; financial relationship (Researcher) with Genentech; financial relationship (Researcher) with Merck; financial relationship (Researcher) with Novartis; financial relationship (Advisor) with Novartis; financial relationship (Advisor) with Astrazenca; financial relationship (Advisor) with Natera; financial relationship (Consultant) with Daiichi Sankyo; financial relationship (Advisor) with RayzeBio; financial relationship (Advisor) with EMD Serono; financial relationship (Advisor) with OncoHost; financial relationship (Advisor) with Merus; financial relationship (Researcher) with Varian; financial relationship (Advisor) with Summit Therapeutics; financial relationship (Researcher) with CellSight; financial relationship (Advisor) with Boerhinger Ingelheim; financial relationship (Advisor) with BioNTech; financial relationship (Grant Or Contract) with CellSight; financial relationship (Advisor) with Eli Lilly; financial relationship (Grant Or Contract) with Genentech; financial relationship (Grant Or Contract) with Merck; financial relationship (Grant Or Contract) with Novartis; financial relationship (Advisor) with Nuvation Bio; financial relationship (Advisor) with Takeda; financial relationship (Grant Or Contract) with Varian.

has a financial relationship (Ownership Interest) with Alessa Therapeutics, Kumquat Biosciences, Olema Pharmaceuticals, Onkure Therapeutics; financial relationship (Consultant) with Boehringer Ingelheim; financial relationship (Contractor) with Xynomic Pharmaceuticals, JS InnoPharm, GlaxoSmithKline (GSK) Pharmaceuticals, InventisBio, Amgen, Revolution Medicines, Scorpion Therapeutics, Nurix Therapeutics, MBrace Therapeutics, Novartis, Frontier Medicines, InventisBio, AbbVie, Corbus Pharmaceuticals, AstraZeneca, MacroGenics, Ensem Therapeutics, Zai Lab, Xadcera Biopharmaceutical, Vividion Therapeutics.

Awaiting faculty disclosure.

has a financial relationship (Professional Service) with Boxer Capital, Globepoint Global Advisors, Johnson & Johnson, Mubadala Capital; financial relationship (Grant Or Contract) with Rain, ADC Therapeutics, ORIC Pharmaceuticals, Takeda Pharmaceuticals, Palleon Pharmaceuticals, Pionyr Therapeutics, Kinnate Biopharma, Gilead Sciences, Mersana Therapeutics, Genentech/Roche, Biohaven Pharmaceuticals, D3 Bio, Merus, Revolution Medicines, Riboscience,Tango Therapeutics.

Awaiting faculty disclosure.

Faculty

has a financial relationship (Professional Service) with Astrazenca; financial relationship (Professional Service) with Trial Library, Inc.

has a financial relationship (Other) with Grail; financial relationship (Advisor) with ClearNote Health.

has a financial relationship (Other) with Abbvie; financial relationship (Other) with Astra Zeneca; financial relationship (Employee) with City of Hope National Medical Center; financial relationship (Researcher) with City of Hope National Medical Center; financial relationship (Other) with Eisai; financial relationship (Advisor) with Genvivo; financial relationship (Other) with J&J.

Awaiting faculty disclosure.

has a financial relationship (Researcher) with BlossomHill Therapeutics; financial relationship (Researcher) with Genentech; financial relationship (Advisor) with Nuvalent Inc.

has a financial relationship (Consultant) with Amgen; financial relationship (Consultant) with GSK; financial relationship (Consultant) with Amgen; financial relationship (Consultant) with Guardant; financial relationship (Consultant) with Pfizer; financial relationship (Speaker) with Pfizer and Amgen.

Awaiting faculty disclosure.

has a financial relationship (Researcher) with AZ; financial relationship (Advisor) with AZ; financial relationship (Other) with Astellas; financial relationship (Other) with AstraZeneca; financial relationship (Advisor) with BMS; financial relationship (Other) with BeOne; financial relationship (Other) with Curio Science; financial relationship (Other) with Guidepoint; financial relationship (Other) with Incyte; financial relationship (Researcher) with Incyte; financial relationship (Other) with MJH Life Sciences; financial relationship (Advisor) with Pfizer; financial relationship (Researcher) with Pfizer; financial relationship (Other) with PreCisca; financial relationship (Researcher) with Takeda.

has a financial relationship (Researcher) with Incyte, SillaJen Inc., Deciphera Pharmaceuticals LLC, Moderna Inc, AstraZeneca LP, Immunitas Therapeutics, Inc., Transcenta Therapeutics, Inc., Bristol Myers Squibb, Adanate, Inc., 23andMe Inc., Gilead Sciences Inc., DOT Therapeutics-1 Inc., PMV Pharmaceuticals, Inc., Astex Pharmaceuticals Inc., Blueprint Medicines Corp., Parabilis Pharmaceuticals, Nuvectis Pharma, Inc.; financial relationship (Ownership Interest) with PATHOMIQ (co-founder), Fortress Biotech, Inc (equity), Sift Biosciences (Equity); financial relationship (Consultant) with Springworks Therapeutics, SeaGen, Bayer, Genome & Company, HarbourBiomed, BPGbio Therapeutics, Oxford Biotherapeutics, Mundibiopharma, BPGbio, Inc., Gilead, Mirati; GI Innovation Inc, XYone Therapeutics, Genome Insight, Aadi Biosciences, MOMA Therapeutics, Daiichi Sankyo, Parabilis, Boehringer Ingelheim Pharmcaeuticals.

Awaiting faculty disclosure.

has a financial relationship (Professional Service) with Bristol-Myers Squibb; financial relationship (Professional Service) with Bristol-Myers Squibb; financial relationship (Professional Service) with Regeneron; financial relationship (Professional Service) with Regeneron; financial relationship (Professional Service) with Merck.

Awaiting faculty disclosure.

has a financial relationship (Advisor) with Tempus; financial relationship (Advisor) with OncoHost.

Awaiting faculty disclosure.

has a financial relationship (Speaker) with Natera; financial relationship (Speaker) with Biotheranostics; financial relationship (Speaker) with Pfizer/Seagen; financial relationship (Consultant) with Gilead Sciences; financial relationship (Consultant) with BAYER; financial relationship () with Astra Zenica; financial relationship (Consultant) with Astra Zenica; financial relationship (Speaker) with Puma Biotechnology.

has a financial relationship (Other) with Pfizer.

has a financial relationship (Advisor) with Tempus Inc.

has a financial relationship (Grant Or Contract) with Replimune; financial relationship (Grant Or Contract) with Inhibrx; financial relationship (Grant Or Contract) with Polaris; financial relationship (Grant Or Contract) with Prelude Therapeutics; financial relationship (Consultant) with Atheneum; financial relationship (Grant Or Contract) with Nested Therapeutics; financial relationship (Consultant) with ANCO; financial relationship (Consultant) with Clearview Health care; financial relationship (Consultant) with Iowa Oncology Society; financial relationship (Grant Or Contract) with Parabilis; financial relationship (Contractor) with Vivace Therapeutics.

Awaiting faculty disclosure.

has a financial relationship (Consultant) with Abbvie; financial relationship (Consultant) with Astrazeneca; financial relationship (Grant Or Contract) with Genentech/Roche, Eli Lilly, BeOne Therapeutics, Kyverna Therapeutics, Cabaletta Bio.

has a financial relationship (Other) with Caris Life Sciences; financial relationship (Other) with Oncohost; financial relationship (Other) with Physician Education Resource; financial relationship (Other) with Meetings Events and Conference Coordinators.

has a financial relationship (Independent) with AbbVie, AstraZeneca, BMS, Merus, Janssen, Novocure, Regeneron; financial relationship (Contractor) with Janssen, Roche/Genentech.

has a financial relationship (Advisor) with Abbratech; financial relationship (Advisor) with Applied Cognition; financial relationship (Ownership Interest) with Crosshair Therapeutics; financial relationship (Advisor) with Enovone; financial relationship (Ownership Interest) with Exposomics; financial relationship (Advisor) with Filtricine; financial relationship (Ownership Interest) with Fodsel; financial relationship (Ownership Interest) with InVu Health; financial relationship (Advisor) with January AI; financial relationship (Advisor) with Jupiter Therapeutics; financial relationship (Advisor) with M3 Helium; financial relationship (Advisor) with Marble Therapeutics; financial relationship (Ownership Interest) with Mirvie; financial relationship (Advisor) with Mitrix; financial relationship (Advisor) with Neuvivo; financial relationship (Advisor) with Next Thought AI; financial relationship (Ownership Interest) with Nimo Therapeutics; financial relationship (Advisor) with Onza; financial relationship (Ownership Interest) with Orange Street Ventures; financial relationship (Advisor) with Personalis; financial relationship (Advisor) with Protos Biologics; financial relationship (Advisor) with Qbio; financial relationship (Advisor) with R42; financial relationship (Advisor) with RTHM; financial relationship (Other) with Repair Biotechnologies; financial relationship (Advisor) with SensOmics; financial relationship (Advisor) with Sigil Biosciences; financial relationship (Advisor) with Swaza; financial relationship (Other) with TranscribeGlass; financial relationship (Advisor) with WndrHLTH; financial relationship (Advisor) with Yuvan Research; financial relationship (Advisor) with iollo; financial relationship (Advisor) with iollo.

No, I have not had a financial relationship with an ineligible company within the past 24 months.

has a financial relationship (Contractor) with WhiteRabbit; financial relationship (Contractor) with Merit Medical.

Awaiting faculty disclosure.